Title: Regorafenib combined with transarterial chemoembolization for unresectable
hepatocellular carcinoma: a real-world study
Version: 1 Date: 09 Apr 2021
Reviewer's report:
This is a well written study on the association of TACE and systemic therapy for second-line
treatment of patients with HCC refractory to sorafenib or levantinib. Despite its merits, the
study has a major methodological issue regarding to its population selection. 13 patients with
metastatic disease were treated with loco-regional therapy, which is something fundamentally
incorrect!
I do not recomendo the publication of this study in its current form, but I urge the authors to
perform a reanalysis of this material excluding this subgroup of patients. These data are still
relevant, and may prove useful in guiding second-line therapy for patients with HCC.
Title: Regorafenib combined with transarterial chemoembolization for unresectable
hepatocellular carcinoma: a real-world study
Version: 1 Date: 09 Apr 2021
Reviewer's report:
This is a well written study on the association of TACE and systemic therapy for second-line
treatment of patients with HCC refractory to sorafenib or levantinib. Despite its merits, the
study has a major methodological issue regarding to its population selection. 13 patients with
metastatic disease were treated with loco-regional therapy, which is something fundamentally
incorrect!
I do not recomendo the publication of this study in its current form, but I urge the authors to
perform a reanalysis of this material excluding this subgroup of patients. These data are still
relevant, and may prove useful in guiding second-line therapy for patients with HCC.
Please review this paper.
user
Title: Regorafenib combined with transarterial chemoembolization for unresectable
hepatocellular carcinoma: a real-world study
Version: 1 Date: 09 Apr 2021
Reviewer's report:
This is a well written study on the association of TACE and systemic therapy for second-line
treatment of patients with HCC refractory to sorafenib or levantinib. Despite its merits, the
study has a major methodological issue regarding to its population selection. 13 patients with
metastatic disease were treated with loco-regional therapy, which is something fundamentally
incorrect!
I do not recomendo the publication of this study in its current form, but I urge the authors to
perform a reanalysis of this material excluding this subgroup of patients. These data are still
relevant, and may prove useful in guiding second-line therapy for patients with HCC.
assistant